Literature DB >> 1697861

Termination of DNA synthesis by 9-beta-D-arabinofuranosyl-2-fluoroadenine. A mechanism for cytotoxicity.

P Huang1, S Chubb, W Plunkett.   

Abstract

The action of 9-beta-D-arabinofuranosyl-2-fluoroadenine (F-ara-A) on DNA synthesis was evaluated both in whole cells and in vitro. 9-beta-D-Arabinofuranosyl-2-fluoroadenine was converted to its 5'-triphosphate 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-triphosphate (F-ara-ATP) in cells and then incorporated into DNA in a self-limiting manner. More than 94% of the analogue was incorporated into DNA at the 3' termini, indicating a chain termination action. In vitro DNA primer extension experiments further revealed that F-ara-ATP compared with dATP for incorporation into the A site of the extending DNA strand. The incorporation of F-ara-AMP into DNA resulted in termination of DNA strand elongation. Human DNA polymerase alpha incorporated more F-ara-AMP into DNA than polymerase epsilon (proliferating cell nuclear antigen-independent DNA polymerase delta) and was more sensitive to inhibition by F-ara-ATP. On the other hand, DNA polymerase epsilon was able to excise the incorporated F-ara-AMP from DNA in vitro. The incorporation of F-ara-AMP into DNA was linearly correlated both with inhibition of DNA synthesis and with loss of clonogenicity; thus it may be the mechanism of cytotoxicity.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1697861

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  55 in total

1.  Killing of chronic lymphocytic leukemia by the combination of fludarabine and oxaliplatin is dependent on the activity of XPF endonuclease.

Authors:  Alma Zecevic; Deepa Sampath; Brett Ewald; Rong Chen; William Wierda; William Plunkett
Journal:  Clin Cancer Res       Date:  2011-06-01       Impact factor: 12.531

2.  Protection against fludarabine neurotoxicity in leukemic mice by the nucleoside transport inhibitor nitrobenzylthioinosine.

Authors:  A A Adjei; L Dagnino; M M Wong; A R Paterson
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

3.  Identification of Non-nucleoside Human Ribonucleotide Reductase Modulators.

Authors:  Md Faiz Ahmad; Sarah E Huff; John Pink; Intekhab Alam; Andrew Zhang; Kay Perry; Michael E Harris; Tessianna Misko; Suheel K Porwal; Nancy L Oleinick; Masaru Miyagi; Rajesh Viswanathan; Chris Godfrey Dealwis
Journal:  J Med Chem       Date:  2015-12-09       Impact factor: 7.446

4.  Resistance to 9-beta-D-arabinofuranosyl-2-fluoroadenine due to reduced incorporation into DNA from competition by excess deoxyadenosine triphosphate: implications for different sensitivities to nucleoside analogues.

Authors:  Nobuyuki Yoshio; Yasukazu Kawai; Hiroki Hori; Takanori Ueda
Journal:  Int J Hematol       Date:  2005-06       Impact factor: 2.490

Review 5.  Fludarabine. A review of its pharmacological properties and therapeutic potential in malignancy.

Authors:  S R Ross; D McTavish; D Faulds
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

6.  Alteration of the carbohydrate for deoxyguanosine analogs markedly changes DNA replication fidelity, cell cycle progression and cytotoxicity.

Authors:  Jessica J O'Konek; Brendon Ladd; Sheryl A Flanagan; Mike M Im; Paul D Boucher; Tico S Thepsourinthone; John A Secrist; Donna S Shewach
Journal:  Mutat Res       Date:  2010-01-08       Impact factor: 2.433

7.  Differential effects of the incorporation of 1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-5-iodouracil (FIAU) on the binding of the transcription factors, AP-1 and TFIID, to their cognate target DNA sequences.

Authors:  K A Staschke; K K Richardson; T E Mabry; A J Baxter; J C Scheuring; D M Huffman; W C Smith; F C Richardson; J M Colacino
Journal:  Nucleic Acids Res       Date:  1996-11-01       Impact factor: 16.971

8.  Role of histone deacetylase inhibitor-induced reactive oxygen species and DNA damage in LAQ-824/fludarabine antileukemic interactions.

Authors:  Roberto R Rosato; Jorge A Almenara; Sonia C Maggio; Stefanie Coe; Peter Atadja; Paul Dent; Steven Grant
Journal:  Mol Cancer Ther       Date:  2008-10       Impact factor: 6.261

9.  4'-Acylated thymidine 5'-triphosphates: a tool to increase selectivity towards HIV-1 reverse transcriptase.

Authors:  A Marx; M Amacker; M Stucki; U Hübscher; T A Bickle; B Giese
Journal:  Nucleic Acids Res       Date:  1998-09-01       Impact factor: 16.971

10.  Fludarabine in the treatment of chronic lymphocytic leukemia: a review.

Authors:  Francesca Ricci; Alessandra Tedeschi; Enrica Morra; Marco Montillo
Journal:  Ther Clin Risk Manag       Date:  2009-03-26       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.